Biotech

All Articles

Lykos will definitely ask FDA to reexamine its choice adhering to rejection of MDMA treatment for post-traumatic stress disorder

.Observing a poor revealing for Lykos Therapeutics' MDMA prospect for trauma at a latest FDA advisor...

AN 2 halves roll call, ceases stage 3 trial after records let down

.AN2 Therapies is reviewing its service in feedback to uninspired midphase data, swearing to give up...

Merck pays for $700M for bispecific, spying autoimmune opening and also possibility to challenge Amgen in cancer

.Merck &amp Co. is actually spending $700 million upfront to test Amgen in a blood cancer market. Th...

Gilead spends J&ampJ $320M to exit licensing offer for seladelpar

.Along With Gilead Sciences on the verge of an FDA choice for its own liver ailment drug seladelpar,...

' All palms on deck' at Lilly as peers target being overweight market

.CEO David Ricks may find the business putting together outdoors tents at basecamp responsible for E...

Entero giving up staff, vacating workplace and stopping R&ampD

.Bed Liquidators has actually turned Entero Therapies white colored as a sheet. The collector bought...

Exelixis loses ADC after deciding it's no match for Tivdak

.Exelixis is actually giving up on its cells factor (TF)- targeting antibody-drug conjugate after co...

Relay loses interest in SHP2 inhibitor after Genentech leaves behind

.Three full weeks after Roche's Genentech system ignored an SHP2 inhibitor deal, Relay Therapeutics ...

Stoke's Dravet disorder med released of predisposed professional grip

.Stoke Therapies' Dravet syndrome drug has actually been devoid of a partial grip, getting rid of th...

Fierce Biotech's Gabrielle Masson offers Ferocious 15 at NYSE

.Strong Biotech Colleague Editor Gabrielle Masson provided the 2024 training class of Ferocious 15 w...